Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- HC Wainwright & Co. analyst Edward White downgraded the rating for Adicet Bio, Inc. (NASDAQ:ACET) from Buy to Neutral. Adicet Bio shares fell 3.4% to close at $1.43 on Tuesday. See how other analysts view this stock.
- B of A Securities analyst Graham Perry downgraded Novartis AG (NYSE:NVS) from Buy to Neutral and lowered the price target from $135 to $130. Novartis shares fell 0.2% to close at $116.99 on Tuesday. See how other analysts view this stock.
- Piper Sandler analyst David Amsellem downgraded the rating for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) from Overweight to Neutral and cut the price target from $41 to $36. Supernus Pharmaceuticals shares fell 1.2% to close at $33.49 on Tuesday. See how other analysts view this stock.
- Truist Securities analyst Gregory Fraser downgraded ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) from Buy to Hold and slashed the price target from $80 to $60. ANI Pharmaceuticals shares fell 5.1% to close at $55.48 on Tuesday. See how other analysts view this stock.
Considering buying NVS stock? Here’s what analysts think:
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
